Understanding Cerebellar Development and Disease
\n \n\n \n \nThe Xue Lab is a translational research group investigating the mechanisms of retinal inflammation and degeneration in the context of age-related macular degeneration (AMD), uveitis and retinal gene therapy. Our aim is to translate improved understanding of disease mechanisms into clinical trials for patients with retinal diseases, and ultimately new therapies to prevent sight loss.
\n \n\n \n \nGlycosylation is one of the most common and poorly understood forms of post-translational modification. Our aim is to understand the biochemical mechanisms underlying protein glycosylation, as well as decipher the roles that they play in health and disease.
\n \n\n \n \nOur group uses multimodal neuroimaging to understand the changes in the brain under anaesthesia and during altered states of consciousness. We aim to translate these findings to the clinical environment to improve patient treatment and outcomes.
\n \n\n \n \nThe Oxford University Global Surgery Group brings together Medical Sciences Division clinicians in surgery, anaesthesia, obstetrics and gynaecology with an interest in global surgical issues.
\n \n\n \n \nOur group applies computational models to study changes in motivation, memory and decision-making that occur in neurological disease. We combine neuroimaging and pharmacological experiments to apply neural network models to clinical problems.
\n \n\n \n \nThe Experimental and Clinical Sleep Medicine group is jointly led by Professor Colin Espie and Professor Simon Kyle. Our research aims to 1) elucidate the mechanisms underpinning chronic sleep disruption; 2) understand the role of sleep disruption in driving adverse health outcomes; and 3) develop interventions to treat sleep and circadian rhythm disruption. We conduct human experimental and clinical studies on sleep and disorders of sleep. Our research programme is supported by the National Institute of Health Research through the Oxford Health Biomedical Research Centre, Health Technology Assessment Programme, and Efficacy and Mechanisms Evaluation Programme, and Wellcome Trust.
\n \n\n \n \nWe bring together biomedical, analytical and clinical expertise to shed new light on the causes that underpin neurodegenerative diseases.
\n \n\n \n \nDrug discovery in neuroscience is very challenging but the need is greater than ever. Perhaps the most important factor for successfully developing an effective therapy, is the identification of human disease relevant drug targets. Our group aims to elucidate the pathophysiological basis of human neurological disorders from genetic molecular networks to complex neural systems using human genetics, human models and human tissue wherever possible.
\n \n\n \n \nOur group aims to achieve a better understanding of what happens in the brains of patients who have just had a subarachnoid haemorrhage, which is a type of stroke.
\n \n\n \n \nCPSD runs several research studies looking into the causes, investigation, and management of large artery atherosclerosis, carotid stenosis, vertebral artery disease and intracranial atherosclerosis.
\n \n\n \n \nThe Oxford Project to Investigate Memory and Ageing (OPTIMA) started in 1988 and the last LEAD participants were seen in March 2015. We are no longer recruiting to any of the cohorts. However, we are currently creating the OPTIMA Legacy Resource from which data collected from the OPTIMA cohorts is available and samples are biobanked and available. Brain tissue is available as part of the Brains For Dementia Research (BDR) collection.
\n \n\n \n \nThe Oxford Vascular Study (OxVasc) investigates vascular diseases (e.g. strokes, heart attacks) in patients registered with eight general practices in Oxfordshire. We run a rapid-access clinic for patients with suspected Transient Ischaemic Attacks (TIAs) or minor strokes.\r\n\r\nAll OxVasc clinics held in the Wolfson Centre for the Prevention of Stroke and Dementia follow Oxford University Hospitals NHS Foundation Trust infection control guidelines.
\n \n\n \n \nBeliefs shape our perception of pain. Using non-invasive magnetic resonance imaging in humans, we investigate how beliefs are generated, maintained and revised in the brain and how they influence pain perception.
\n \n\n \n \nDeveloping methods to accurately and objectively measure neurological disorders such as Parkinson\u2019s Disease and Progressive Supranuclear Palsy.
\n \n\n \n \nWe study why certain neuronal populations are vulnerable to neurodegeneration and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.
\n \n\n \n \nOur research aims to understand the characteristics of individual brain tumours, combining cutting edge brain imaging, molecular neuropathology and neurosurgical techniques to develop personalized approaches for first-line cancer surgery.
\n \n\n \n \nThe Emerging Technologies for Analysis of the Brain (ETA) Research Group is a multidisciplinary team leveraging emerging technologies across neuropathology, neuroimmunology, neurodegeneration, neuro-oncology, and molecular genetics to drive innovative insights into brain health and diseases.
\n \n\n \n \n